{"id":4099,"date":"2021-02-16T21:37:03","date_gmt":"2021-02-17T05:37:03","guid":{"rendered":"https:\/\/depts.washington.edu\/pandemicalliance\/?p=4099"},"modified":"2021-02-16T21:37:03","modified_gmt":"2021-02-17T05:37:03","slug":"sensitivity-of-infectious-sars-cov-2-b-1-1-7-and-b-1-351-variants-to-neutralizing-antibodies","status":"publish","type":"post","link":"https:\/\/depts.washington.edu\/pandemicalliance\/2021\/02\/16\/sensitivity-of-infectious-sars-cov-2-b-1-1-7-and-b-1-351-variants-to-neutralizing-antibodies\/","title":{"rendered":"Sensitivity of Infectious SARS-CoV-2 B.1.1.7 and B.1.351 Variants to Neutralizing Antibodies"},"content":{"rendered":"<p><i>[Pre-print, not peer reviewed]<\/i> The SARS-CoV-2 B.1.1.7 variant (first described in the UK) was experimentally shown to have similar sensitivity to the neutralizing activity of convalescent sera (n=83) collected up to 9 months post symptom onset compared to the wild-type virus. In contrast, neutralizing titers had a mean 6-fold reduction against the B.1.351 variant (first described in South Africa) and a loss of neutralizing activity in 40% of convalescent sera at 9 months post symptom onset.<span class=\"Apple-converted-space\">\u00a0<\/span><\/p>\n<p>Among sera from 19 vaccinees collected at various timepoints during the vaccination regimen, neutralizing titers were lower against the B.1.1.7 variant and to a greater extent against the B.1.351 variant compared to the wild-type virus. After the second dose, at a 1\/30 serum dilution, 80% of sera neutralized the wild-type and the B.1.1.7 variant but only 60% neutralized the B.1.351 variant.<\/p>\n<p>No neutralizing activity against the wild-type virus and the variants was detected in the nasal swabs from the vaccinees 2-3 weeks post vaccination, except among 3 vaccinees who had a history of SARS-CoV-2 infection. Neutralizing activity was similar for the wild-type virus and B.1.1.7 variant, but was absent for the B.1.351 variant.<\/p>\n<p><i>Planas et al. (Feb 12, 2021). Sensitivity of Infectious SARS-CoV-2 B.1.1.7 and B.1.351 Variants to Neutralizing Antibodies. Pre-print downloaded Feb 16 from <\/i><a href=\"https:\/\/doi.org\/10.1101\/2021.02.12.430472\">https:\/\/doi.org\/10.1101\/2021.02.12.430472<\/a><i><span class=\"Apple-converted-space\">\u00a0<\/span><\/i><\/p>\n","protected":false},"excerpt":{"rendered":"<p>[Pre-print, not peer reviewed] The SARS-CoV-2 B.1.1.7 variant (first described in the UK) was experimentally shown to have similar sensitivity to the neutralizing activity of convalescent sera (n=83) collected up to 9 months post symptom onset compared to the wild-type virus. In contrast, neutralizing titers had a mean 6-fold reduction against the B.1.351 variant (first&#8230;<\/p>\n<div><a class=\"more\" href=\"https:\/\/depts.washington.edu\/pandemicalliance\/2021\/02\/16\/sensitivity-of-infectious-sars-cov-2-b-1-1-7-and-b-1-351-variants-to-neutralizing-antibodies\/\">Read more<\/a><\/div>\n","protected":false},"author":7,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_links_to":"","_links_to_target":""},"categories":[6],"tags":[159],"topic":[31],"class_list":["post-4099","post","type-post","status-publish","format-standard","hentry","category-article-summary","tag-variants","topic-vaccines-and-immunity"],"_links":{"self":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/4099","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/comments?post=4099"}],"version-history":[{"count":1,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/4099\/revisions"}],"predecessor-version":[{"id":4100,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/4099\/revisions\/4100"}],"wp:attachment":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/media?parent=4099"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/categories?post=4099"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/tags?post=4099"},{"taxonomy":"topic","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/topic?post=4099"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}